Overview

High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors

Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this trial is to evaluate the efficacy and safety of two dose schedules of activated recombinant human factor VII in treatment of joint bleeds in haemophilia patients with inhibitors.
Phase:
Phase 4
Details
Lead Sponsor:
Novo Nordisk A/S